Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 5
2011 2
2012 7
2013 16
2014 21
2015 38
2016 33
2017 39
2018 41
2019 58
2020 43
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

273 results
Results by year
Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Two patients randomly assigned to mogamulizumab withdrew consent before receiving study treatment; thus, 370 patients were included in the safety population. Mogamulizumab therapy resulted in superior investigator-assessed progression-free survival compared with vor …
Two patients randomly assigned to mogamulizumab withdrew consent before receiving study treatment; thus, 370 patients were included i …
Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
Sato T, Coler-Reilly ALG, Yagishita N, Araya N, Inoue E, Furuta R, Watanabe T, Uchimaru K, Matsuoka M, Matsumoto N, Hasegawa Y, Yamano Y. Sato T, et al. N Engl J Med. 2018 Feb 8;378(6):529-538. doi: 10.1056/NEJMoa1704827. N Engl J Med. 2018. PMID: 29414279 Free article. Clinical Trial.
METHODS: In this uncontrolled, phase 1-2a study, we assessed the safety, pharmacokinetics, and efficacy of mogamulizumab in patients with glucocorticoid-refractory HAM-TSP. In the phase 1 dose-escalation study, 21 patients received a single infusion of mogamulizumab
METHODS: In this uncontrolled, phase 1-2a study, we assessed the safety, pharmacokinetics, and efficacy of mogamulizumab in patients …
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Moore DC, et al. Ann Pharmacother. 2020 Apr;54(4):371-379. doi: 10.1177/1060028019884863. Epub 2019 Oct 25. Ann Pharmacother. 2020. PMID: 31648540 Review.
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, dosing, and administration of mogamulizumab for the treatment of T-cell lymphomas. Data Sources: A literature search of PubMed (1966 to September 2019) was conducted using the keywords mogamulizu
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, dosing, and administration of mogamulizumab for the treatm …
Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H, Kamachi K, Kimura S. Ureshino H, et al. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):326-331. doi: 10.1016/j.clml.2019.03.004. Epub 2019 Mar 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30981611 Review.
Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. ...It is possible that the efficacy of mogamulizumab could be established by the occurrence of skin …
Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
Ollila TA, Sahin I, Olszewski AJ. Ollila TA, et al. Onco Targets Ther. 2019 Feb 7;12:1085-1094. doi: 10.2147/OTT.S165615. eCollection 2019. Onco Targets Ther. 2019. PMID: 30799938 Free PMC article. Review.
Common adverse effects include rash and infusion reactions, which are usually low grade. Sentinel reports indicate that exposure to mogamulizumab may result in severe or refractory graft vs host disease after allogeneic bone marrow transplantation, highlighting the need fo …
Common adverse effects include rash and infusion reactions, which are usually low grade. Sentinel reports indicate that exposure to mogam
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, Wandroo F, Feldman T, Taylor GP, Sawas A, Humphrey J, Kurman M, Moriya J, Dwyer K, Leoni M, Conlon K, Cook L, Gonsky J, Horwitz SM; 0761-009 Study Group. Phillips AA, et al. Haematologica. 2019 May;104(5):993-1003. doi: 10.3324/haematol.2018.205096. Epub 2018 Dec 20. Haematologica. 2019. PMID: 30573506 Free PMC article. Clinical Trial.
The most frequent treatment-related adverse (grade 3) events with mogamulizumab were infusion-related reaction and thrombocytopenia (each 9%). ...Investigator's choice chemotherapy did not result in tumor response in this trial; however, mogamulizumab treatment resu …
The most frequent treatment-related adverse (grade 3) events with mogamulizumab were infusion-related reaction and thrombocytopenia ( …
Mogamulizumab for the treatment of T-cell lymphoma.
Makita S, Tobinai K. Makita S, et al. Expert Opin Biol Ther. 2017 Sep;17(9):1145-1153. doi: 10.1080/14712598.2017.1347634. Epub 2017 Jul 3. Expert Opin Biol Ther. 2017. PMID: 28649848 Review.
Then, the authors discuss the current clinical development of mogamulizumab and its clinical implications for T-cell lymphomas. Expert opinion: Mogamulizumab has potent clinical efficacy against CCR4-positive T-cell lymphomas, especially against ATL. Among various t …
Then, the authors discuss the current clinical development of mogamulizumab and its clinical implications for T-cell lymphomas. Exper …
Mogamulizumab.
[No authors listed] [No authors listed] 2019 Apr 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31643268 Free Books & Documents. Review.
Mogamulizumab is a humanized monoclonal antibody to the T cell CC chemokine receptor 4 which is used to treat peripheral and cutaneous T-cell lymphomas. Mogamulizumab is associated with a low rate of serum enzyme elevations during treatment and has been linked to se
Mogamulizumab is a humanized monoclonal antibody to the T cell CC chemokine receptor 4 which is used to treat peripheral and cutaneou
Mogamulizumab in the treatment of advanced mycosis fungoides and Sezary syndrome: safety and efficacy.
Lewis DJ, Rook AH. Lewis DJ, et al. Expert Rev Anticancer Ther. 2020 Jun;20(6):447-452. doi: 10.1080/14737140.2020.1760096. Epub 2020 Apr 28. Expert Rev Anticancer Ther. 2020. PMID: 32320304
AREAS COVERED: Phase I-III clinical trials involving mogamulizumab demonstrated its significant efficacy and tolerability. ...Since it eliminates malignant T cells via ADCC, combining mogamulizumab with immunotherapeutic agents such as interferons, interleukin-12, a …
AREAS COVERED: Phase I-III clinical trials involving mogamulizumab demonstrated its significant efficacy and tolerability. ...Since i …
Mogamulizumab.
[No authors listed] [No authors listed] 2020 Jul 20. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 30272896 Free Books & Documents. Review.
No information is available on the passage of mogamulizumab into breastmilk. Because mogamulizumab is a large protein molecule with a molecular weight of 149,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destro …
No information is available on the passage of mogamulizumab into breastmilk. Because mogamulizumab is a large protein molecule …
273 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page